An analysis of the receiver operating characteristic curve (ROC) showed that the CSF levels of neurogranin may significantly discriminate AD patients from controls (AUC = 0.919, 95% CI 78.4–99.55, p < 0.001), with 81% accuracy, 82% specificity, and 79% sensitivity. The gene discussed is NRGN; the disease is Alzheimer disease.